Treatment and participant characteristics: all groups.

*ELV has not received regulatory approval. This group was excluded from the analysis. SD, standard deviation; TDF, tenofovir; FTC, emtricitabine; AZT, zidovudine; 3TC, lamivudine; d4T, stavudine; ddI, didanosine; ABC, abacavir; ELV, elvucitabine; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase strand transfer inhibitor; CCR5, chemokine receptor 5 inhibitor; HIV, human immunodeficiency virus; MSM, men who have sex with men; IDU, injecting drug use; AIDS, acquired immune deficiency syndrome; Ab, antibody; sAg, surface antigen; cp, copies.